Glenmark, Lannett, Bausch, Apotex, Heritage and Emcure have agreed to pay about $96.5 million to resolve claims that they took part in a generic drug price-fixing conspiracy, according to California Attorney General Rob Bonta’s office. The money is a separate pool from the one Sandoz is paying, and it comes from a case brought by California and 47 other states and territories. For consumers who bought generic prescriptions over a ten-year stretch, the six companies add a second source of potential compensation.
The two pools should not be merged into one fund. The California Attorney General’s September 24 announcement puts the six-company total at approximately $96.5 million and describes Sandoz’s settlement as part of a separate complaint filed earlier in 2026. The New York Attorney General’s office, which announced the Sandoz deal on October 1, treats the earlier company settlements as distinct from it.
Who the settlements cover: generic purchases from May 2009 through December 2019
The settlements reach consumers who bought eligible generic prescription drugs between May 2009 and December 2019. The covered drugs are the ones listed on the claims administrator’s website, www.AGGenericDrugs.com, which also takes claims by phone at 1-866-290-0182. A purchase counts only if the drug appears on that list and the sale falls inside the window, so a consumer who filled generic prescriptions during those years has to match the specific drug names and dates against the administrator’s list rather than assume coverage.
Whether a particular household is included depends on records from a decade ago: which generic drugs were bought, from which pharmacy, and in which month between May 2009 and December 2019. The Settlement & Refund Recovery System includes the four-date rule for reading a settlement notice and a step-by-step filing walkthrough, which line up with the purchase-window question the generic drug notices raise.
Check the generic drug settlement window against your records →
Bonta framed the outreach in his announcement: “As a result of our efforts to hold generic drug manufacturers accountable for illegally conspiring to drive up prices, consumers may now be eligible to receive compensation.” The wording is conditional, and the releases do not publish a per-person payment amount, so no figure for an individual claim can be stated.
Both attorneys general give the same claim deadline, March 8, 2027. The claim is made to the administrator, not to the individual drug companies, and not through the attorneys general’s offices.
Which six companies make up the $96.5 million
The California release names the six: Glenmark, Lannett, Bausch, Apotex, Heritage and Emcure, the parent company of Heritage. Teva, which was named in a separate 2019 complaint in the same litigation, is not among them. The release gives the combined figure of about $96.5 million rather than a company-by-company breakdown.
The New York Attorney General’s release recaps the earlier deals by timing and by company. It lists Apotex and Heritage at $49.1 million combined, announced in November 2024; Lannett and Bausch at $17 million combined, in February 2026; and Glenmark at more than $29 million, in July 2026. Those are New York’s figures for the individual settlements, and they are reported there at that scope. Emcure’s share is not itemized in either release, so no sum of the parts is offered here; the $96.5 million is California’s figure for the six.
The states allege that the companies were part of a coordinated scheme to fix prices and rig bids on generic drugs. New York’s release describes it as “a broad, coordinated, and systematic conspiracy to fix prices, avoid competition, and rig bids for more than 100 different generic drugs.” California’s account adds that the defendants used phrases such as “fair share,” “playing nice in the sandbox” and “responsible competitor” to discourage competition. These are the states’ allegations in the complaints that led to the settlements.
Why two separate pools matter for a claim
The Sandoz payment and the six-company pool come from different defendants and different complaints, brought by the same coalition of 48 attorneys general. New York’s release gives Sandoz’s payment as $320,560,180 in principal, rising to $400 million with interest over seven years. That payment is not part of the $96.5 million and is not added to it here.
Both announcements point consumers to the same administrator, and the two releases give the same purchase window and the same deadline. The practical effect is that one set of purchase records can be matched against more than one settlement. A claim record that notes which drug, which date and which pharmacy supports that matching, whichever company’s settlement a given drug turns out to fall under.
New York Attorney General Letitia James said in her office’s release: “Generic drug price increases make it harder for working families throughout New York to afford the medications they need. Sandoz and other companies made illegal backroom deals to boost their profits by coordinating to raise drug prices, and now we are ensuring the consumers who were harmed get the justice they deserve.”
Matching ten years of pharmacy purchases to the administrator’s drug list
The free official route starts with the attorneys general. California’s announcement directs consumers to the administrator at www.AGGenericDrugs.com or 1-866-290-0182, where the list of covered drugs and the claim process are kept. Typing the administrator’s address directly into a browser, rather than following a link in an unsolicited email or text, is the safer way to reach it, since settlement notices are a common lure for scam messages.
Before opening the claim, it helps to gather whatever records exist for the window: pharmacy printouts, insurer explanation-of-benefits statements, Medicare Part D summaries, flexible spending or health savings account statements, and loyalty-program histories from pharmacy chains. Many pharmacies can reprint a prescription history on request. The task is to match each drug name on the list to a purchase date between May 2009 and December 2019; purchases outside that range do not count.
The date that governs everything is March 8, 2027, the deadline both attorneys general give. A claim that uses the administrator’s list and a clear record of drug, date and pharmacy is the thing the process turns on, and nothing in either release suggests the deadline is flexible.
The Settlement & Refund Recovery System pairs a claim log and payment tracker, a 5-tab Excel tracker, for recording each drug, purchase date and claim status, with a step-by-step filing walkthrough for working through an administrator’s form. It is a paid, optional tool that sits next to the free official route and does not file claims or decide who is eligible.
Open the claim log and tracker for the generic drug settlements →
This article was produced with AI assistance and reviewed by The Financial Wire’s editorial team.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
